{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:55:46Z","timestamp":1773892546261,"version":"3.50.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Targeting CD20 with the monoclonal antibody rituximab has improved survival in patients with aggressive B-cell lymphomas, the majority of which are cured with chemoimmunotherapy. Patients progressing through or relapsing after their treatment have a poor prognosis. Despite a number of promising novel agents with efficacy in relapsed disease, randomized trials building on the chemoimmunotherapy backbone have failed to show further survival benefit. Significant progress has been made in the last few years in relapsed or refractory disease with the emergence of therapies that harness the patient\u2019s immune system to fight disease. The approval of 2 chimeric antigen receptor T-cell products has provided potential for curative therapy, although challenges remain with toxicities and access. The approval of the antibody drug conjugate polatuzumab in combination with chemoimmunotherapy has offered survival benefit to patients who are not candidates for more aggressive approaches and has the potential to change the standard of care for initial management. Several targeted agents have proven effective, but the majority do not produce durable responses, requiring development in combination with other targeted or conventional therapies. Herein, promising targets in aggressive lymphoma with the greatest potential for improving outcomes in these patients are discussed. Novel therapies, their toxicities, and their potential role in initial or subsequent treatment are highlighted.<\/jats:p>","DOI":"10.1182\/hematology.2020000093","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T02:57:41Z","timestamp":1607137061000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Novel targets in aggressive lymphoma"],"prefix":"10.1182","volume":"2020","author":[{"given":"Kami","family":"Maddocks","sequence":"first","affiliation":[{"name":"The Ohio State University, Columbus, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2020121621170200200_B1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"6769","key":"2020121621170200200_B2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"5","key":"2020121621170200200_B3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published correction appears in Nat Med. 2018;24:1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2020121621170200200_B4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2020121621170200200_B5","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"issue":"27","key":"2020121621170200200_B6","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"2020121621170200200_B7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"2020121621170200200_B8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"2020121621170200200_B9","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2020121621170200200_B10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2020121621170200200_B11","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"2020121621170200200_B12","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"2020121621170200200_B13","article-title":"Long-term outcomes from the phase II LMIND study of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma [abstract]","author":"Salles","year":"2020"},{"issue":"23","key":"2020121621170200200_B14","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2020121621170200200_B15","article-title":"Initial results of a phase 2 study of Loncastuximab tesirine, a novel pyrrolobenzodiazepine-based antibody\u2013drug conjugate, in relapsed or refractory diffuse large B cell lymphoma [abstract]","author":"Carlo-Stella","year":"2020"},{"issue":"8","key":"2020121621170200200_B16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3324\/haematol.2017.168401","article-title":"A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy","volume":"103","author":"Trn\u0115n\u00fd","year":"2018","journal-title":"Haematologica"},{"issue":"11","key":"2020121621170200200_B17","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"15 suppl","key":"2020121621170200200_B18","article-title":"Updated safety and long-term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR2017) in R\/R aggressive NHL [abstract]","volume":"36","author":"Abramson","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020121621170200200_B19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood-2018-99-110142","article-title":"Phase I experience with a bi-specific CAR targeting CD19 and CD22 in adults with B-cell malignancies","volume":"132","author":"Hossain","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621170200200_B20","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1182\/blood-2018-99-110194","article-title":"A phase 1 study with point-of-care manufacturing of dual targeted, tandem antiCD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-Hodgkin lymphoma","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2020121621170200200_B21","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"2020121621170200200_B22","doi-asserted-by":"crossref","first-page":"Abstract 6","DOI":"10.1182\/blood-2019-123742","article-title":"Mosunetuzumab induced complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines [abstract]","volume":"134","author":"Schuster","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621170200200_B23","article-title":"Clinical activity of REGN1979, a bispecific human, anti-CD20 x anti-CD3 antibody, in patients with relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL) [abstract]","volume":"134","author":"Bannerji","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2020121621170200200_B24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020121621170200200_B25","article-title":"The first-in-class anit-CD47 antibody HU5F9-G4 with rituximab induces durable response in relapsed\/refractory DLBCL and indolent lymphoma: interim phase 1B\/2 results","author":"Advani","year":"2019"},{"issue":"2","key":"2020121621170200200_B26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020121621170200200_B27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"13","key":"2020121621170200200_B28","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621170200200_B29","article-title":"Phase 2 results of the iR2 regimen (ibrutinib, lenalidomide, and rituximab) in patients with relapsed\/refractory (r\/r) non-germinal center B cell-like (non-GCB) diffuse large B cell lymphoma (DLBCL) [abstract]","volume":"134","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2020121621170200200_B30","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib alone and in combination with standard chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma: final phase II results [abstract]","volume":"134","author":"Westin","year":"2019","journal-title":"Blood"},{"issue":"24","key":"2020121621170200200_B31","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma [published correction appears in Blood 2020;136(2):259]","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"2020121621170200200_B32","article-title":"A phase 2B study of selinexor in patients with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) [abstract]","author":"Kalakonda"},{"issue":"7","key":"2020121621170200200_B33","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood.V99.7.2285","article-title":"The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile","volume":"99","author":"Huang","year":"2002","journal-title":"Blood"},{"issue":"20","key":"2020121621170200200_B34","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab\u2013CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"2020121621170200200_B35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/hon.2437_121","article-title":"Prognostic impact of BCL2 and MYC expression and translocation in untreated DLBCL: results from the phase III GOYA study","volume":"35","author":"Sehn","year":"2017","journal-title":"Hematol Oncol"},{"issue":"8","key":"2020121621170200200_B36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"2020121621170200200_B37","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"issue":"suppl 2","key":"2020121621170200200_B38","first-page":"Abstract 079","article-title":"Improved outcomes in patients (pts) with BCL2-positive diffuse large B cell lymphoma (DLBCL) treated with venetoclax plus R-CHOP [abstract]","volume":"7","author":"Morschhauser","year":"2019","journal-title":"Hematol Oncol"},{"issue":"15 suppl","key":"2020121621170200200_B39","article-title":"Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas [abstract]","volume":"38","author":"Rutherford","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/101\/1794930\/hem2020000093c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2020\/1\/101\/1794930\/hem2020000093c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T18:13:18Z","timestamp":1608315198000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2020\/1\/101\/474348\/Novel-targets-in-aggressive-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2020000093","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}